Cherington Charles's Form 4 filing
Comera Life Sciences Holdings, Inc.CMRA · filed Jan 3, 2024
- Accession no.
- 0001104659-24-001041
- Filed
- Jan 3, 2024, 8:38 PM ET
- Trade date
- Dec 27-29, 2023
- Filing delay
- 7 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 derivative transactions. It was filed 7 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cherington CharlesCIK 0001448698 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2023 | Common Stock | PPurchaseAcquired | +10,325,454 | $567,900.00 | – | – | Direct | Price outlier |
| Dec 29, 2023 | Common Stock | PPurchaseAcquired | +20,650,908 | $0.00F1 | $0 | 20,650,908 | Direct | |
| Dec 27, 2023 | Common Stock | PPurchaseAcquired | +310,153 | $500,000.00 | +$1,947,765,000 | 3,895.53 | Indirect | Price outlier |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof.
Referenced by the price of 1 transaction in Table II.